The derivative suit targets the medical testing giant’s directors, CEO, chief financial officer, and chief information officer. It accuses them of failing to address “persistently deficient cybersecurity measures” even after the first major cyberattack on American Medical Collection Agency, which took place across eight months in 2018-2019.
Those board-level oversights left LabCorp vulnerable to a separate malware attack and then a second AMCA breach earlier ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.